Autoimmune Disease Diagnostics Market Growth & Trends
The global autoimmune disease diagnostics market size is estimated to reach USD 8.20 billion by 2030, expanding at a CAGR of 6.18% from 2025 to 2030, according to a new report by Grand View Research, Inc. Government organizations along with related associations strive to curb such high healthcare costs and simultaneously provide improved diagnostic and therapeutic solutions to the patients. This has resulted in increased funding by the NIH for R&D programs related to autoimmune diseases.
Moreover, the presence of favorable government initiatives aimed at curbing the incidence of these diseases and developing viable diagnostic & treatment options is expected to drive market growth over the forecast period.
Growing volume of autoimmune diagnostic procedures has heightened the need for instruments and facilities rendering faster and effective results. In an attempt to cater to ever-increasing procedure volumes, diagnostic laboratories are rapidly moving toward automation. Lab automation helps decrease workload via rapid turnaround times and helps generate standardized & reproducible results.
Autoimmune Disease Diagnostics Market Report Highlights
- The localized autoimmune disease diagnostics segment dominated the market and accounted for a revenue share of 64.25% in 2024.
- The consumables & assays segment accounted for the largest revenue share of 70.43% in 2024. Every laboratory diagnostic test utilizes test kits, reagents, and antibodies.
- In terms of test type, the antinuclear antibody tests dominated the market with a revenue share of 42.62% in 2024. The growth of this segment is attributed to affordability, high sensitivity, and extensive availability.
- The hospital segment dominated the market in 2024 with a revenue share of 53.32%. The high share is attributed to the increased adoption of autoimmune disease diagnostic practices in hospitals for various diseases.
- The North America autoimmune disease diagnostics market dominated the global industry and accounted for a revenue share of 42.70% in 2024. The Asia Pacific autoimmune disease diagnostics market is anticipated to witness a fastest CAGR from 2024 to 2030.
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.1.1.1. Type segment
- 1.1.1.2. Product segment
- 1.1.1.3. Test Type segment
- 1.1.1.4. End use segment
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Objectives
- 1.4.1. Objective - 1
- 1.4.2. Objective - 2
- 1.4.3. Objective - 3
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR’s Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary research
- 1.7. Information or Data Analysis
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.10. List of Secondary Sources
- 1.11. List of Abbreviations
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Type and Test Type Snapshot
- 2.3. Product and End Use Snapshot
- 2.4. Competitive Landscape Snapshot
- Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Presence of research funding programs
- 3.2.1.2. Presence of favorable government initiatives
- 3.2.1.3. Growing patient awareness levels
- 3.2.1.4. Technological innovation in the form of lab automation
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Slow diagnostic result turnaround times and lack of skilled healthcare practitioners
- 3.3. Industry Analysis Tools
- 3.3.1. Porter’s Five Forces Analysis
- 3.3.2. PESTEL Analysis
- Chapter 4. Type Business Analysis
- 4.1. Autoimmune Disease Diagnostics Market: Type Movement Analysis
- 4.2. Systemic Autoimmune Disease Diagnostics
- 4.2.1. Systemic Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 4.2.2. Rheumatoid Arthritis Diagnostics
- 4.2.2.1. Rheumatoid Arthritis Diagnostics Market, 2018 - 2030 (USD Million)
- 4.2.3. Ankylosing Spondylitis Diagnostics
- 4.2.3.1. Ankylosing Spondylitis Diagnostics Market, 2018 - 2030 (USD Million)
- 4.2.4. Systemic Lupus Erythematosus (SLE) Diagnostics
- 4.2.4.1. Systemic Lupus Erythematosus (SLE) Diagnostics Market, 2018 - 2030 (USD Million)
- 4.2.5. Other Systemic Autoimmune Disease Diagnostics
- 4.2.5.1. Other Systemic Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 4.3. Localized Disease Diagnostics
- 4.3.1. Localized Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 4.3.2. Multiple sclerosis diagnostics
- 4.3.2.1. Multiple Sclerosis Diagnostics Market, 2018 - 2030 (USD Million)
- 4.3.3. Type 1 Diabetes Diagnostics
- 4.3.3.1. Type 1 Diabetes Diagnostics Market, 2018 - 2030 (USD Million)
- 4.3.4. Hashimoto's Thyroiditis Diagnostics
- 4.3.4.1. Hashimoto's Thyroiditis Diagnostics Market, 2018 - 2030 (USD Million)
- 4.3.5. Idiopathic Thrombocytopenic Purpura (ITP) diagnostics
- 4.3.5.1. Idiopathic Thrombocytopenic Purpura (ITP) diagnostics Market, 2018 - 2030 (USD Million)
- 4.3.6. Other Localized Autoimmune Disease Diagnostics
- 4.3.6.1. Other Localized Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- Chapter 5. Product Business Analysis
- 5.1. Autoimmune Disease Diagnostics Market: Product Movement Analysis
- 5.2. Instruments
- 5.2.1. Instruments Market, 2018 - 2030 (USD Million)
- 5.3. Consumables and Assays
- 5.3.1. Consumables and Assays Market, 2018 - 2030 (USD Million)
- Chapter 6. Test Type Business Analysis
- 6.1. Autoimmune Disease Diagnostics Market: Test Type Movement Analysis
- 6.2. Antinuclear Antibody Tests
- 6.2.1. Antinuclear Antibody Tests Market, 2018 - 2030 (USD Million)
- 6.3. Autoantibody Tests
- 6.3.1. Autoantibody Tests Market, 2018 - 2030 (USD Million)
- 6.4. C-reactive Protein (CRP)
- 6.4.1. C-Reactive Protein (CRP) Market, 2018 - 2030 (USD Million)
- 6.5. Complete Blood Count (CBC)
- 6.5.1. Complete Blood Count (CBC) Market, 2018 - 2030 (USD Million)
- 6.6. Urinalysis
- 6.6.1. Urinalysis Market, 2018 - 2030 (USD Million)
- 6.7. Others
- 6.7.1. Others Market, 2018 - 2030 (USD Million)
- Chapter 7. End Use Business Analysis
- 7.1. Autoimmune Disease Diagnostics Market: End Use Movement Analysis
- 7.2. Hospitals
- 7.2.1. Hospitals Market, 2018 - 2030 (USD Million)
- 7.3. Diagnostic Centers
- 7.3.1. Diagnostic Centers Market, 2018 - 2030 (USD Million)
- 7.4. Others
- 7.4.1. Others Market, 2018 - 2030 (USD Million)
- Chapter 8. Regional Business Analysis
- 8.1. Autoimmune Disease Diagnostics Market Share By Region, 2024 & 2030
- 8.2. North America
- 8.2.1. SWOT Analysis
- 8.2.2. North America Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.2.3. U.S.
- 8.2.3.1. Key Country Dynamics
- 8.2.3.2. Target Disease Prevalence
- 8.2.3.3. Competitive Scenario
- 8.2.3.4. Regulatory Framework
- 8.2.3.5. U.S. Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.2.4. Canada
- 8.2.4.1. Key Country Dynamics
- 8.2.4.2. Target Disease Prevalence
- 8.2.4.3. Competitive Scenario
- 8.2.4.4. Regulatory Framework
- 8.2.4.5. Canada Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.2.5. Mexico
- 8.2.5.1. Key Country Dynamics
- 8.2.5.2. Target Disease Prevalence
- 8.2.5.3. Competitive Scenario
- 8.2.5.4. Regulatory Framework
- 8.2.5.5. Mexico Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3. Europe
- 8.3.1. SWOT Analysis
- 8.3.2. Europe Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.3. UK
- 8.3.3.1. Key Country Dynamics
- 8.3.3.2. Target Disease Prevalence
- 8.3.3.3. Competitive Scenario
- 8.3.3.4. Regulatory Framework
- 8.3.3.5. UK Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.4. Germany
- 8.3.4.1. Key Country Dynamics
- 8.3.4.2. Target Disease Prevalence
- 8.3.4.3. Competitive Scenario
- 8.3.4.4. Regulatory Framework
- 8.3.4.5. Germany Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.5. France
- 8.3.5.1. Key Country Dynamics
- 8.3.5.2. Target Disease Prevalence
- 8.3.5.3. Competitive Scenario
- 8.3.5.4. Regulatory Framework
- 8.3.5.5. France Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.6. Italy
- 8.3.6.1. Key Country Dynamics
- 8.3.6.2. Target Disease Prevalence
- 8.3.6.3. Competitive Scenario
- 8.3.6.4. Regulatory Framework
- 8.3.6.5. Italy Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.7. Spain
- 8.3.7.1. Key Country Dynamics
- 8.3.7.2. Target Disease Prevalence
- 8.3.7.3. Competitive Scenario
- 8.3.7.4. Regulatory Framework
- 8.3.7.5. Spain Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.8. UK
- 8.3.8.1. Key Country Dynamics
- 8.3.8.2. Target Disease Prevalence
- 8.3.8.3. Competitive Scenario
- 8.3.8.4. Regulatory Framework
- 8.3.8.5. UK Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.9. Sweden
- 8.3.9.1. Key Country Dynamics
- 8.3.9.2. Target Disease Prevalence
- 8.3.9.3. Competitive Scenario
- 8.3.9.4. Regulatory Framework
- 8.3.9.5. Sweden Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.10. Norway
- 8.3.10.1. Key Country Dynamics
- 8.3.10.2. Target Disease Prevalence
- 8.3.10.3. Competitive Scenario
- 8.3.10.4. Regulatory Framework
- 8.3.10.5. Norway Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.3.11. Denmark
- 8.3.11.1. Key Country Dynamics
- 8.3.11.2. Target Disease Prevalence
- 8.3.11.3. Competitive Scenario
- 8.3.11.4. Regulatory Framework
- 8.3.11.5. Denmark Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.4. Asia Pacific
- 8.4.1. SWOT Analysis
- 8.4.2. Asia Pacific Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.4.3. Japan
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Target Disease Prevalence
- 8.4.3.3. Competitive Scenario
- 8.4.3.4. Regulatory Framework
- 8.4.3.5. Japan Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.4.4. China
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Target Disease Prevalence
- 8.4.4.3. Competitive Scenario
- 8.4.4.4. Regulatory Framework
- 8.4.4.5. China Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.4.5. India
- 8.4.5.1. Key Country Dynamics
- 8.4.5.2. Target Disease Prevalence
- 8.4.5.3. Competitive Scenario
- 8.4.5.4. Regulatory Framework
- 8.4.5.5. India Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.4.6. Australia
- 8.4.6.1. Key Country Dynamics
- 8.4.6.2. Target Disease Prevalence
- 8.4.6.3. Competitive Scenario
- 8.4.6.4. Regulatory Framework
- 8.4.6.5. Australia Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.4.7. Thailand
- 8.4.7.1. Key Country Dynamics
- 8.4.7.2. Target Disease Prevalence
- 8.4.7.3. Competitive Scenario
- 8.4.7.4. Regulatory Framework
- 8.4.7.5. Thailand Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.4.8. South Korea
- 8.4.8.1. Key Country Dynamics
- 8.4.8.2. Target Disease Prevalence
- 8.4.8.3. Competitive Scenario
- 8.4.8.4. Regulatory Framework
- 8.4.8.5. South Korea Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.5. Latin America
- 8.5.1. SWOT Analysis
- 8.5.2. Latin America Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.5.3. Brazil
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Target Disease Prevalence
- 8.5.3.3. Competitive Scenario
- 8.5.3.4. Regulatory Framework
- 8.5.3.5. Brazil Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.5.4. Argentina
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Target Disease Prevalence
- 8.5.4.3. Competitive Scenario
- 8.5.4.4. Regulatory Framework
- 8.5.4.5. Argentina Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.6. MEA
- 8.6.1. SWOT Analysis
- 8.6.2. MEA Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.6.3. South Africa
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Target Disease Prevalence
- 8.6.3.3. Competitive Scenario
- 8.6.3.4. Regulatory Framework
- 8.6.3.5. South Africa Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.6.4. Saudi Arabia
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Target Disease Prevalence
- 8.6.4.3. Competitive Scenario
- 8.6.4.4. Regulatory Framework
- 8.6.4.5. Saudi Arabia Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.6.5. UAE
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Target Disease Prevalence
- 8.6.5.3. Competitive Scenario
- 8.6.5.4. Regulatory Framework
- 8.6.5.5. UAE Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- 8.6.6. Kuwait
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Target Disease Prevalence
- 8.6.6.3. Competitive Scenario
- 8.6.6.4. Regulatory Framework
- 8.6.6.5. Kuwait Autoimmune Disease Diagnostics Market, 2018 - 2030 (USD Million)
- Chapter 9. Competitive Landscape
- 9.1. Company Categorization
- 9.2. Strategy Mapping
- 9.3. Company Market Share Analysis, 2024
- 9.4. Company Profiles/Listing
- 9.4.1. F. Hoffmann-La Roche Ltd
- 9.4.1.1. Overview
- 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.1.3. Product Benchmarking
- 9.4.1.4. Strategic Initiatives
- 9.4.2. Siemens Healthcare Private Limited
- 9.4.2.1. Overview
- 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.2.3. Product Benchmarking
- 9.4.2.4. Strategic Initiatives
- 9.4.3. Abbott
- 9.4.3.1. Overview
- 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.3.3. Product Benchmarking
- 9.4.3.4. Strategic Initiatives
- 9.4.4. Beckman Coulter, Inc.
- 9.4.4.1. Overview
- 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.4.3. Product Benchmarking
- 9.4.4.4. Strategic Initiatives
- 9.4.5. Danaher Corporation
- 9.4.5.1. Overview
- 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.5.3. Product Benchmarking
- 9.4.5.4. Strategic Initiatives
- 9.4.6. Quest Diagnostics
- 9.4.6.1. Overview
- 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.6.3. Product Benchmarking
- 9.4.6.4. Strategic Initiatives
- 9.4.7. EUROIMMUN Medizinische Labordiagnostika AG
- 9.4.7.1. Overview
- 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.7.3. Product Benchmarking
- 9.4.7.4. Strategic Initiatives
- 9.4.8. Nova Diagnostics Pte Ltd.
- 9.4.8.1. Overview
- 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.8.3. Product Benchmarking
- 9.4.8.4. Strategic Initiatives
- 9.4.9. BIOMÉRIEUX
- 9.4.9.1. Overview
- 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.9.3. Product Benchmarking
- 9.4.9.4. Strategic Initiatives
- 9.4.10. Hemagen Diagnostics, Inc.
- 9.4.10.1. Overview
- 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.4.10.3. Product Benchmarking
- 9.4.10.4. Strategic Initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook